NCT06359860View on ClinicalTrials.gov

A Study of ST-1898 for Unresectable or Metastatic Melanoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Unresectable or Metastatic Melanoma
Interventions
DRUG

ST-1898 tablets

Supplied as 5 mg and 40 mg tablets

Trial Locations (1)

100142

RECRUITING

Peking University Cancer Hospital & Institute, Beijing

Sponsors
All Listed Sponsors
lead

Beijing Scitech-Mq Pharmaceuticals Limited

INDUSTRY